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| INTRODUC TI ON
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease and is the fourth leading cause of cancer-associated mortality. 1 The difference between the incidence and the death rate is still small due to its early distant spread and the lack of efficacious current therapies. 2, 3 Whole exome and genome sequencing have identified PDAC as a disease of high genetic variability including core gene alterations and general copy number variations. [4] [5] [6] However, for personalized treatment strategies, efforts to date in targeting key oncogenic pathways have reported unsatisfied results. 7, 8 A wide range of interactive and/or redundant pathways may be simultaneous activated when blocking a single pathway, resulting in less effect in solid tumors, especially for aggressive or drug-resistant tumors. 9, 10 Thus, targeting a variety of tumor-driven gene therapies will become an important strategy for PDAC.
Recently, human unique prolyl isomerase PIN1 has been indicated to exhibit profound functions in pathogenesis of cancer disease by amplifying numerous oncoproteins and then disrupting its balance with tumor suppressors. 11 PIN1 is a central controller in the regulation of proline-directed phosphorylation, which is a common event relating to tumorigenesis. 12, 13 Overactivation or upregulation of PIN1 contributes to carcinogenesis in the majority of human tumors, including PDAC, [14] [15] [16] [17] [18] [19] whereas alteration of PIN1 single nucleotide polymorphisms (SNP) at the promoter region has inverse results. 20 In addition, PIN1 is likely to be an indispensable orchestrator in the process of oncogene-driven carcinogenesis. [21] [22] [23] [24] Given that Pin1−/− homozygous mice grow normally and there are no general side effects on normal cells, 25 PIN1 is a potential molecular target for cancer treatment. Notably, targeting of PIN1 has been achieving some promising results in animal studies on leukemia, triple negative breast cancer and hepatocellular carcinoma. [26] [27] [28] [29] However, little evidence on the function of PIN1 in the progression of PDAC has been seen.
The PIN1 inhibitor has been explored for 2 decades. Clinical use has not been widespread because of the lack of required specificity and cell permeability, but this could change with the identification of all trans retinoic acid (ATRA) as a PIN1 inhibitor based on high-throughput screen (HTS) technology. 11, 26 ATRA can induce cell cycle arrest, apoptosis and epithelial cell differentiation of PDAC to inhibit tumor cell growth. 30, 31 However, paradoxical results after ATRA treatment in different PDAC cells were observed. 32, 33 Similar findings 26 were obtained regarding ATRA for different breast cancer cells. However, cellular susceptibility against ATRA depends on the level of PIN1 expression and the degree of phosphorylation at S71 of PIN1. 26 ATRA can bind to the catalytically active sites of PIN1
and subsequently inhibit its activity, resulting in PIN1 protein degradation. Furthermore, ATRA exerts potent antitumor activity against multiple refractory cancers through inhibiting and ablating PIN1 to inactivate multiple oncogenes or activate tumor suppressors simultaneously in vivo. [26] [27] [28] [29] However, the role of ATRA and its targeting PIN1 in PDAC remain elusive.
Thus, in this present study, we examined the expression of PIN1 and explored the role of PIN1 in the pathogenesis of PDAC. The association between PIN1 and clinical pathological features was also examined. We showed that PIN1 was upregulated in pancreatic cancer and metastatic tissues. High PIN1 expression is significantly associated with shorter survival and stratified with outcomes in patients. Genetic and chemical PIN1 inhibition decreased not only the growth but also the invasiveness of PDAC cells through regulating the key molecules of multiple cancer-driving signaling pathways simultaneously. Furthermore, such PIN1 ablation inhibited both the tumorigenesis and metastatic spread and reduced tumor burden in vivo. Thus, PIN1 may be a promising biomarker and a potential therapeutic target for PDAC disease.
| MATERIAL S AND ME THODS

| Patients and tissues
A total of 173 consecutive cases at the First Affiliated Hospital of Fujian Medical University were collected from the years 2006 to 2016. All original H&E slides were reviewed and patients' clinical pathological parameters were retrieved from the medical records.
Disease-free survival (DFS) was defined as the duration from the date of initial diagnosis to the first detection of pancreatic cancerspecific relapse or death. Overall survival (OS) was defined as the duration from the date of initial diagnosis to the date of death. None of the patients were dead within 1 month after surgery. Tissue microarray (TMA) was constructed for immunohistochemistry (IHC).
For the TMA construction, 3 representative regions of each H&E-stained slides were chosen, from the center, the edge of the tumor and the peri-tumoral tissues, respectively; 2.5 mm cores at each corresponding area were taken and brought into "recipient" paraffin blocks by manual operation. Serial 4-μm sections were cut and transferred to SuperfrostPlus glass slides (Matsunami Glass Industry, Japan 
| Stable PIN1 knockdown cell construction
Cells for PIN1 knockdown (KD) were infected with the lentiviruses expressing PIN1 shRNA or Scrambled, selected with puromycin (2 μg/mL). Briefly, the validated PIN1 shRNA (5′-CCACCGTCACACAGTATTTAT-3′) 35, 36 was subcloned into the pKLO.1 lentiviral vector and generated, and was transfected into 293T cells with the helper plasmids (pVSVG, pMDL and pREV) for 48-72 h. The supernatant containing virus was collected and stored.
All the plasmids used were provided from Dr Kun Ping Lu as described previously. Fisher's exact test, *P < 0.05; **P < 0.01.
| Cell proliferation assays
| Migration and invasion assays
TA B L E 1 Relationship between PIN1 expression and clinicopathological features
F I G U R E 1 PIN1 expression in pancreatic ductal carcinoma (PDAC) and association with outcomes. A, B, Representative immunochemical staining of PIN1 expression in paracarcinoma and tumor tissues (A, scale bar = 20 μm) and analyzed (B, n = 173). C, D, Kaplan-Meier analysis of overall survival (OS) (C) and disease-free survival (DFS) (D) according to PIN1 expression in PDAC. E, Representative illustrations of PIN1 expression in primary tumor and its paired metastatic tissues and analyzed (scale bar = 20 μm, n = 30). F, G, H, Comparisons of OS between PIN1 expression in patients with TNM stage 2b (F), same moderate histological grade (G) and no lymph node involvement (H). (Fisher's exact test, the paired t test and the log-rank test were used; *P < 0.05, **P < 0.01, ***P < 0.001) to migrate for 24 h or 48 h and stained with crystal violet. For invasion assays, cells were inserted into the upper chamber with a Matrigel coated membrane (Sigma, St.Louis, MO, USA).
Migrated cells adhering to the underside of the inserts were photographed (AXIO Observer Z1, Carl Zeiss, Gottingen, Germany) and counted.
| Western blotting analysis
Cells were lysed in ice cold RIPA buffer and quantified using a BCA Protein Assay Kit (Beyotime, Shanghai, China). Proteins were separated and then transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5% milk and incubated with primary antibodies. After washing, the membranes were incubated with (HRP) conjugated secondary antibodies and enhanced with a chemiluminescence HRP substrate (Millipore, Burlington, MA, USA). F I G U R E 2 Genetic PIN1 suppression affected pancreatic ductal carcinoma (PDAC) cell functions in vitro. Stable PIN1 knockdown (KD) of PANC1 and BXPC3 cells with RNA interference and their controls were used, respectively. A, PIN1 KD cells resulted in marked reduction of PIN1 expression determined by immunoblot. B, PIN1 KD decreased in cell proliferation. C, D, PIN1 KD decreased cell colony formation. E, F, PIN1 KD reduced both migration and invasion. G, Cell lysates of PIN1 KD and controls were performed by immunoblot with specific antibodies. (All experiments were performed independently at least 3 times. Data are shown as mean ± SEM. One-way ANOVA and Student's t test were used; *P < 0.05, **P < 0.01.) a microscope. For ATRA treatments, the mice were grouped into receive ATRA-releasing pellets after metastatic nodules were confirmed by histological evaluation. The time of death of the mice was recorded.
| Animal studies
| Statistical analysis
The findings were analyzed using the statistical software SPSS for Figure S1B , P = 0.002). However, the gene copy number of PIN1 was increased only in a small fraction of cases ( Figure S1C ) and no significant result was found in comparison with peripheral blood and pancreas tissues ( Figure   S1D , P = 0.293).
Regarding the potential significance of PIN1 location in cancer tissues, we analyzed the relationship between the different locations and the clinicopathological features regardless of the intensity of PIN1 staining. PIN1 expression both in the cytoplasm and nucleus was significantly associated with histological grade (P = 0.001) and nerve invasion (P = 0.007), whereas no significant results were found between the groups that were PIN1 negative and cytoplasmic positive (Table S2 ). However, with dichotomization of PIN1 expression (average immunoscore = 97 as threshold)
into high or low groups combining the percentage and intensity of PIN1 expression, high PIN1 expression was strongly significantly associated with tumor diameter (P = 0.05), histological grade (P = 0.001), lymph node involvement (P = 0.009) and nerve invasion (P = 0.006) in PDAC (Table 1) . PIN1 low or high expression was shown to be an independent prognostic factor by multivariate Cox analysis for both DFS and OS in PDAC (Table 2) Similar trends were also shown in patients with the same moderate histological grade ( Figure 1G ) or with no lymph node involvement ( Figure 1H ).
| Genetic PIN1 suppression inhibits both proliferation and invasiveness of pancreatic ductal adenocarcinoma cells in vitro
PIN1 was upregulated in pancreatic cancer tissues and several human pancreatic ductal cells. 19 Next, we verify the functions of PIN1 in PDAC using PANC1 (poorly differentiated cells) 37 and BXPC3 (highly metastatic cells) 38 F I G U R E 3 Genetic PIN1 suppression affected pancreatic ductal carcinoma (PDAC) cell functions in vivo. Xenograft tumor and tail vein transport models were constructed with PANC1 and BXPC3 PIN1KD and their control cells, respectively. A, PIN1 knockdown (KD) modulated tumor volume growth in vivo (n = 6). B, Photographic illustration of tumors collected from nude mice. C, PIN1 KD-induced tumor weight lost in vivo (n = 6, measured at the end point).
D, E, Representative illustrations of PIN1, Cyclin D1 and Ki67 expression in xenograft tumor tissues (D) and analyzed (E). F, Photographic illustrations of hearts and lungs collected from nude mice (red arrows indicate the tumor nodules). G, PIN1 KD decreased the capability of metastatic spread in vivo (n = 6). H, Representative histomorphology and expression of
Vimentin and E-cadherin in lung metastatic nodules of mice. (Data are shown as mean ± SEM. One-way ANOVA and Student's t test were used; *P < 0.05, **P < 0.01, ***P < 0.001.)
PIN1 can activate more than 40 oncogenes whereas inactivate at least 20 tumor suppressing genes. 11 To address the underlying mechanisms of PIN1-mediated tumorigenesis, we detected downstream molecules that have been demonstrated to be substrates of PIN1. Monitors of G1/S phase transition, Notch1 signaling and AKT/mTOR pathway are the core signaling pathways in relation to pancreatic carcinogenesis, 6 which could be regulated by PIN1. [39] [40] [41] [42] [43] [44] As expected, PIN1KD cells decreased the expression of these oncoproteins, including Cyclin D1, CDK2, Notch1 and pser473Akt, and increased suppressor p27 kip . Changes in EMT-related protein were observed in PIN1KD cells. although notable downregulation of Vim was observed in PANC1 cells, there was notable upregulation of Ecad in BXPC3 cells ( Figure 2G ).
| Genetic PIN1 suppression inhibits tumor growth and metastatic spread for pancreatic ductal adenocarcinoma cells in vivo
To F I G U R E 4 PIN1 chemical inhibitor all trans retinoic acid (ATRA) affected pancreatic ductal carcinoma (PDAC) cell functions in vitro. Both PANC1 and BXPC3 cells were performed with different doses of ATRA treatments. A, B, ATRA inhibited cell proliferation. C, D, ATRA decreased cell colony formation. E, F, ATRA reduced both migration and invasion. G, Cell lysates with ATRA treatments were performed by immunoblot with specific antibodies. (All experiments were performed independently at least 3 times. Data are shown as mean ± SEM. Oneway ANOVA and Student's t test were used; *P < 0.05, **P < 0.01,***P < 0.001.)
PDAC is a lethal disease with an overall 5-year survival rate of less than 5% due to early distant spread. 
| D ISCUSS I ON
The search for an alternative means or a targeted agent for PDAC management has been ongoing for several years. Pancreatic ductal adenocarcinoma is fundamentally a genetic disease with frequent genetic mutations. [26] [27] [28] [29] For normal immortalized cells or hepatocelluar carcinoma cells with PIN1KD, ATRA treatments showed no effect on inhibition of cell proliferation, 26, 29 which was also observed in our F I G U R E 5 PIN1 chemical inhibitor all trans retinoic acid (ATRA) affected pancreatic ductal carcinoma (PDAC) cell functions in vivo. Xenograft tumor and tail vein transport models were constructed with PANC1 and BXPC3 cells, respectively. Different doses of slowreleasing ATRA pellets were given for 21 d. A, ATRA decreased tumor volumes in vivo. B, Photographic illustration of tumors collected from nude mice. C, ATRA induced endogenous PIN1 degradation determined by immunoblot in xenograft tumor samples. D, ATRA induced tumor weight lost in vivo (measured at the end point). E, F, Statistical analysis on PIN1 (E) and Ki67 (F) expression in xenograft tumor tissues. G, ATRA reduced metastatic nodules in vivo. H, Kaplan-Meier survival analysis for ATRA-treated and control mice. I, Representative histomorphology and expression of Vimentin and E-cadherin in lung metastatic nodules of mice. (Data shown as mean ± SEM. One-way ANOVA, Student's t test and the log-rank test were used, respectively; *P < 0.05, **P < 0.01,***P < 0.001.)
PIN1KD cells. Thus, PIN1 is a mainly target for ATRA treatment and PIN1 degradation is important for anticancer therapy in PDAC.
When we used slow-releasing ATRA pellets that can maintain ATRA serum concentrations in mice constantly enough to induce PIN1 inhibition, 26 ATRA exhibited great potent anticancer effects in tumor models. This formulation of ATRA significantly reduced tumor burden and improved the OS of mice. Thus, it is urgent to develop a new longer-acting ATRA or a more specific and potent PIN1 inhibitor to treat PDAC.
In summary, the results of this study support the role of PIN1 in PDAC progression. We found that PIN1 was highly expressed in most PDAC tissues and significantly correlated with the worst outcomes in patients. Here, we provided further evidence for the use of PIN1 as a promising therapeutic target in PDAC. Genetic and chemical PIN1 inhibition exerted potent antitumor activity through blocking multiple cancer-driving pathways in PDAC. Longer half-life ATRA or more potent and specific PIN1 targeting inhibitors could be exploited to treat this aggressive cancer.
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